Real-world evidence shows 34% reduction in risk of death with Ibrance in metastatic breast cancers
01 April 2022
- Recently published data have shown Ibrance (palbociclib) in combination with letrozole being associated with improved real-world progression-free survival and overall survival in women with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) metastatic breast cancer
- These data indicate a 42% reduction in the risk of progression and a 34% reduction in the risk of death when taking Ibrance in combination with letrozole as opposed to letrozole alone
- “Real-world evidence is woven into the fabric of how we innovate and advance care for patients with breast cancer, supporting our randomized clinical trials,”
Chris Boshoff, M.D., Ph.D.,
Chief Development Officer, Oncology, Pfizer Global Product DevelopmentClick here to learn more.